Insider · CIK 0001979163
Peter DeMuth
Files at ELTX (Elicio Therapeutics, Inc.). First filing -, latest -.
In brief
Peter DeMuth files SEC Form 4 as officer at ELTX (Elicio Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Peter DeMuth has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 8 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 16, 2026 | ELTX Elicio Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +52,832 | $0.00 | $0 | 52,832 | Jul 17, 2026 |
| Feb 2, 2026 | ELTX Elicio Therapeutics, Inc. | AGrant or award Common Stock | +20,800 | $0.00 | $0 | 21,543 | Feb 3, 2026 |
| Feb 2, 2026 | ELTX Elicio Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +41,600 | $0.00 | $0 | 41,600 | Feb 3, 2026 |
| Dec 9, 2025 | ELTX Elicio Therapeutics, Inc. | MOption exercise Common Stock | +362 | $4.41 | $1,596 | 743 | Dec 10, 2025 |
| Dec 9, 2025 | ELTX Elicio Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -362 | $0.00 | $0 | 0 | Dec 10, 2025 |
| Feb 3, 2025 | ELTX Elicio Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +44,400 | $0.00 | $0 | 44,400 | Feb 4, 2025 |
| Dec 16, 2024 | ELTX Elicio Therapeutics, Inc. | MOption exercise Common Stock | +381 | $4.41 | $1,680 | 381 | Dec 18, 2024 |
| Dec 16, 2024 | ELTX Elicio Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -381 | $0.00 | $0 | 0 | Dec 18, 2024 |
Questions about Peter DeMuth
Answered from the filings on this page, as of the latest one.
Is Peter DeMuth buying or selling?
Peter DeMuth has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Peter DeMuth's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Peter DeMuth has 0.
Where does Peter DeMuth file Form 4?
Peter DeMuth has filed Form 4 at ELTX (Elicio Therapeutics, Inc.) as Chief Scientific Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.